National Institutes of Health Advisory Committee to the Director

Ebola in 2014: The Perfect Storm

Anthony S. Fauci, M.D.

Director
National Institute of Allergy and
Infectious Diseases

National Institutes of Health

December 11, 2014





- Ebola background
- Current outbreak in West Africa
- Ebola in the USA
- Role of research and development
 - Diagnostics
 - Vaccines
 - Therapeutics







- Ebola background
- Current outbreak in West Africa
- Ebola in the USA
- Role of research and development
 - Diagnostics
 - Vaccines
 - Therapeutics








Ebola Virology


- Filovirus family
- Species and average fatality in the genus Ebolavirus
 - Bundibugyo − ~30%
 - Zaire 50-90%
 - Reston animal disease
 - Sudan ~50%
 - Taï Forest 1 non-fatal human case



EM of Ebola virus particles (green) attached to Vero cell (blue). NIAID

Ebola Virology


- Filovirus family
- Species and average fatality in the genus Ebolavirus
 - Bundibugyo − ~30%
 - Zaire 50-90%
 - Reston animal disease
 - Sudan ~50%
 - Taï Forest 1 non-fatal human case



EM of Ebola virus particles (green) attached to Vero cell (blue). NIAID

Ebola Transmission Cycle

Enzootic cycle Epizootic cycle




Fruit bats putative reservoir; evidence inconclusive

Ebola Transmission Routes

Bodily fluids


Objects (fomites)



Transmission occurs once symptomatic (viral load rises at symptom onset)

Infected animals

Typical Ebola Virus Disease Clinical Course



Exposure

Incubation period

Average 8-10 days, range 2-21

Symptoms begin

Days 1-3
Weakness, Vomiting, fever, diarrhea, influenza-like hypotension illness

Days 7-10
Confusion,
possible
bleeding
(typically
minor),
shock

Recovery or death



Ebola Virus Disease in West Africa — Clinical Manifestations and Management

DS Chertow et al.

- Experience with 700 Ebola Patients in Monrovia, Liberia
- August 23 October 4, 2014
- Médecins sans Frontières Ebola Treatment Unit

Evidence of Lack of Transmissibility During Early Febrile Stage of Ebola Virus Disease (EVD)

- Early sxs of EVD high fever, malaise, fatigue, body aches ("flu-like")
- GI sxs begin 3-5 days later: epigastric pain, then nausea, vomiting and diarrhea

Upon careful history, no patient contracted EVD from an infected person during early febrile illness


- Ebola background
- Current outbreak in West Africa
- Ebola in the USA
- Role of research and development
 - Diagnostics
 - Vaccines
 - Therapeutics









State of the Outbreak: March 2014




State of the Outbreak: May 2014




State of the Outbreak: July 2014




State of the Outbreak: Sept. 2014




State of the Outbreak: Oct. 2014




State of the Outbreak: Nov. 2014



State of the Outbreak: Dec. 2014



Ebola Outbreaks 1976 to Present Day



Source: Nature Vol 514:284, 2014; WHO

Factors Facilitating Spread

- Poor nations with limited health infrastructure
- No prior experience with Ebola
- Few health professionals; multiple health threats
- Frequent travel across porous borders
- Limited cooperation between neighboring governments
- History of regional conflicts
- Local customs, e.g., burial practices





Epidemiology and Genomic Sequencing of the Outbreak

99 genome sequences from 78 individuals (May-June 2014): 395 mutations

No evidence of significant functional change



Genomic Surveillance
Elucidates Ebola
Virus Origin and
Transmission During
the 2014 Outbreak

SK Gire, PC Sabeti, et al.

The Link between Viral Mutation and Transmissibility



Ebola in the Air? A Nightmare That Could Happen

Elizabeth Cohen



"There really are no examples of a virus that has completely changed its method of transmissibility. It can get a little bit more virulent, a little bit less virulent... But to completely change its method of transmission would be unprecedented."

- Anthony S. Fauci, M.D. Senate Appropriations Hearing, November 12, 2014

Volume 179 Suppl. 1 February, 1999

The Journal of Infectious Diseases

Transmission of Ebola Hemorrhagic Fever: A Study of Risk Factors in Family Members, Kikwit, Democratic Republic of the Congo, 1995

SF Dowell, CJ Peters et al.

- 173 household contacts of EVD patients
- No transmissions to those without direct physical contact with patient

Public Health Response to Ebola in Affected Countries

- Education
- Hygiene practices
- Case identification
- Contact tracing
- Personal Protective Equipment for caregivers
- Prompt isolation
- Aggressive supportive care
- Safe burials







International Response to Ebola Outbreak: U.S. Response



"Faced with this outbreak, the world is looking to us, the United States, and it's a responsibility that we embrace... We are going to keep leading in this effort."

-President Barack Obama, Sept. 16, 2014

- 3,000+ troops
- Construction of Ebola Treatment Units (ETUs)
- 25-bed facility for healthcare workers
- Ongoing CDC and USAID support

- Ebola background
- Current outbreak in West Africa
- Ebola in the USA
- Role of research and development
 - Diagnostics
 - Vaccines
 - Therapeutics







USA TODAY

October 14, 2014

Fear Spreads Faster than Ebola: Our View


By USA Today Editorial Board



Ebola in the USA

- Deliberate air evacuation of identified Ebola patients: Brantly, Writebol, Sacra, Mukpo, Salia, Crozier
- Inadvertent importation of infected persons:
 - Traveler Thomas Duncan
 - Health care worker Craig Spencer
- Health Care Worker infected in the USA Nina Pham and Amber Vinson at Texas Presbyterian

Medevacs from West Africa




Source: ECDC

August 2014: Infections Reported in American Aid Workers

The Washington Post

August 1, 2014

U.S. Confirms 2 Americans with Ebola Coming Home for Treatment




Kent Brantly, MD



Nancy Writebol

Additional Medevac Cases




Inadvertent Importation of Ebola: First Case Diagnosed in U.S

THE WALL STREET JOURNAL

September 30, 2014

First Case of Ebola in U.S. Is Confirmed



First Case Diagnosed in the U.S.: Timeline

Sept 19

Subject departs Monrovia



Sept 20

Arrives and departs Brussels, Belgium

Sept 20

Arrives in Dallas



Sept 24

Develops symptoms



Sept 26

Presents to ER, sent home



Sept 28

Patient transferred by ambulance, admitted



Sept 30

Tests positive for Ebola



Oct 8

Patient dies

First Two Ebola Transmissions Within the U.S.

The New York Times

October 12, 2014

Texas Health Worker Tests Positive for Ebola

2nd Ebola Case in U.S. Stokes Fears of Health Care Workers

NIH Special Clinical Studies Unit: Designated Ebola Treatment Facility







The Washington Post

October 25, 2014

Nina Pham, Nurse Who Contracted Ebola, is Now Free of Virus and Leaves NIH








Photo: Nina Pham



How to Stop Ebola in America: Ban Air Travel from West Africa

Dr. David B. Samadi

Airport Screening for Ebola Virus Infection



Exit screening:

- Fever
- Presence of symptoms
- Contact with Ebola patient
- Refuse exit if necessary

Entry screening in the U.S.:

- All passengers routed through 5 airports
- Fever
- Presence of symptoms
- Contact with Ebola patient
- Isolate and further evaluate if warranted

Exit Screening at West African Airports



Airport Exit and Entry Screening for Ebola — August-November 10, 2014

- August–October 2014, 80,000 travelers screened on exit from Guinea, Liberia and Sierra Leone; 12,000 en route to U.S.
- Of passengers denied boarding due to symptoms or high-risk exposure, none diagnosed with Ebola

Entry Screening in the United States



Airport Exit and Entry Screening for Ebola — August-November 10, 2014

- Oct 11-Nov 10, 2014: 1,993 persons screened for Ebola after arrival from Guinea, Liberia or Sierra Leone; none symptomatic during travel
- 86 referred to CDC officers; 7 of 86 found to be symptomatic and referred for medical evaluation
- None had Ebola



October 23, 2014

Doctor Who Treated Ebola Patients Rushed to NYC Hospital



The New York Times


October 24, 2014

New York and New Jersey Will Quarantine Medical Workers

Isolation vs. Quarantine

Isolation separates sick people with a contagious disease

Quarantine separates people exposed but not ill



The right balance must be guided by scientific evidence



Direct contact without proper PPE with infected bodily fluids or with body of Ebola patient



- Close contact with symptomatic patient without proper PPE
- Direct contact in proper PPE with symptomatic person in widespread-transmission area



- Travel to widespread-transmission area within 21 days
- Brief contact e.g., shaking hands with symptomatic Ebola patient
- Same room or airplane with symptomatic Ebola patient
- Direct contact in proper PPE with symptomatic person in U.S.



Contact with Ebola patient before symptoms

CDC Guidelines for Individuals Potentially Exposed to Ebola

Risk Level Monitoring Travel Public **Activities** High Risk **Direct Active** Restricted Restricted Some Risk Direct Active Case-by-Case Case-by-Case Low Risk Yes – Direct No No **Active for some** No Risk No No

Source: CDC

^{*} Direct Active for healthcare workers who have worked in ETUs in Sierra Leone, Liberia and Guinea with *no known exposure*


- Ebola background
- Current outbreak in West Africa
- Ebola in the USA
- Role of research and development
 - Diagnostics
 - Vaccines
 - Therapeutics








Pipeline of Vaccines



Pipeline of Vaccines





Chimpanzee Adenovirus Vaccine Generates Acute and Durable Protective Immunity Against Ebolavirus Challenge

DA Stanley, NJ Sullivan et al.

- Prime-boost Ebola vaccine tested: NIAID/GSK Chimp Ad3 vector + single MVA vector boost
- First demonstration of durable protection against Ebola in 4/4 rhesus macaques




Chimpanzee Adenovirus Vector Ebola Vaccine — Preliminary Report


JE Ledgerwood, BS Graham, the VRC 207 Study Team, et al.

- Phase I clinical trial of 20 healthy volunteers aged 18-50 yrs, two dose groups (2x10e10 and 2x10e11)
 - Well tolerated (two fevers, both resolved in 24 hrs)
 - Antibody and CD8+ T cell responses at higher dose consistent with protective non-human primate response

Pipeline of Vaccines



Pipeline of Therapeutics



Source: Adapted from Nature News, Sept 2, 2014



September 26, 2014

Experimental Therapies: Growing Interest in the Use of Whole Blood or Plasma from Recovered Ebola Patients (Convalescent Therapies)

SCIENTIFIC AMERICAN

December 1, 2014

Is the Blood of Ebola Survivors an Effective Treatment?

Looking Ahead

Continue to focus on West Africa

Prepare for future outbreaks: Global Health Security Agenda

Move towards eliminating to the extent possible disparities of health care infrastructure in developing world